AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00942695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1.5PD
Description: average American diet plus 1.5 oz per day pistachios
Study NCT00942695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3.0PD
Description: average American diet plus 3.0 oz per day pistachios
Study NCT00942695 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: average American diet without pistachios
Study NCT04208074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participants will exercise under the supervision of expert personal trainers and follow an optimized exercise program tailored to the strength and fitness level of each participant. Participants will exercise for 16 weeks; 2 days a week at the gym for an hour and 2 days of the week at home for 45 minutes.
Study NCT01483469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: orally daily, 14 days
Study NCT01483469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO5011232
Description: \[11C\]-RO5011232 intravenously
Study NCT01483469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5011232
Description: \[11C\]-RO5011232 intravenously
Study NCT04269564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stepwise PEEP
Description: * a PEEP of 4 cmH2O will be used after intubation till 5 minutes after pneumoperitonium, and adjusted in a step wise approach after lung ultrasound by adding 2 cmH2O, repeating ultrasound 5 minutes after every change in peep till no lung collapse is detected by lung ultrasound with a maximal peep of 10 cmH2O, or if hemodynamic instability occurs.~* Lung ultrasound examination will be performed at a minimum three times in each patient; the first will be performed 1 min after starting mechanical ventilation of the lungs, 5 minutes after pneumoperitonium, 5 min after every peep increase in stepwise peep group and the last time at the end of the surgery.~We define anaesthesia-induced atelectasis to be significant if any region has a consolidation score of ≥ 2.
Study NCT02785536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RITCh Treatment
Description: The RITCh treatment increased the emphasis on stress management, negative affect management and utilized language and activities to foster an internal locus of control. Activities were added to address impulsive decision-making, develop home smoking policies, increase the positive valance of treatment, and address barriers to use of the nicotine patches. The treatment materials were also tailored with numerous examples relevant to lower SES groups and African Americans. For example: stress management components specifically address financial stress, discrimination, and micro-aggressions; treatment utilization components include reinforcing the value of individual contributions to the group, structured positive feedback among group members at every session, sending missed you post cards signed by all group members to participants who miss a treatment session, specifically addressing myths about nicotine patch use, and practicing the application of nicotine patches together.
Study NCT02785536 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: The components of the standard treatment include education and activities in which participants gain an understanding of the biopsychosocial underpinnings of tobacco dependence and the cue-urge-response cycle of smoking. Interventions include self-monitoring, guided scheduled rate reduction, treatment goal setting, medication education, stress management, cognitive and behavioral strategies for managing cravings and cues, problem-solving, conflict management, enhancing social support, relapse prevention, and cigarette refusal training. A participant workbook was provided that corresponded to the activities in the treatment sessions.
Study NCT02016261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: The subjects will be prescribed Fluvoxamine treatment for 24 weeks with dose 50-300 mg
Study NCT00545675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abilify(aripiprazole)
Description: Abilify and Depakote in 24-week treatment of mania in patients with bipolar disorder
Study NCT00545675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Depakote (divalproate)
Description: Placebo and Depakote in 24-week treatment of mania in patients with bipolar disorder
Study NCT02833766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-EGFR-IL-dox
Description: First-line treatment with anti-EGFR-IL-dox, given at a dose of 50 mg/m2 intravenous, on day 1 of each cycle, cycle length is 28 days
Study NCT03050060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT03050060 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy
Study NCT03050060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03050060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir Mesylate
Description: Given PO
Study NCT02345174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2849330
Description: GSK2849330 solution (100 mg/mL) for infusion diluted in 0.9% sodium chloride to the appropriate concentration for the dose.
Study NCT02345174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-GSK2849330
Description: 89Zr-GSK2849330 solution for intravenous administration diluted with GSK2849330 Solution for Infusion (unlabelled GSK2849330) with a target radioactivity of 37MBq and a total antibody concentration of 0.4 mg/mL or 1.2 mg/mL.
Study NCT03050060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03050060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02400424 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 54 Gy in 3 fractions D1-D3-D5. SBRT should be started within 3 to 4 weeks after the end of radiochemotheray (RT-CT).
Study NCT04031638 — intervention group
Intervention type: OTHER
Intervention: Radioactive Iodine treatment
Description: Patients with a thyroid tumor who received radioactive Iodine treatment.
Study NCT01881386 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging (MRI)
Description: Magnetic Resonance Spectroscopy
Study NCT04801394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hernioplastic and insertion of FLaPp® composite mesh
Description: After the reduction of the large incisional hernia, the polypropylene transparent film of this mesh (lower flap) was sutured to the margins of the residual peritoneum and posterior rectus sheath as a neo-peritoneum; the macroporous light polypropylene layer (upper flap) was then sutured circumferentially with full-thickness transabdominal stitches in the retromuscular space.
Study NCT02839941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Subjects will receive iguratimod orally, twice a day, for consecutive 52 weeks
Study NCT02277678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid administration oxycodone
Description: Epidural administration single dose through epidural catheter
Study NCT02277678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid administration morphine
Study NCT02839941 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Mycophenolate mofetil
Description: All subjects will receive mycophenolate mofetil for consecutive 52 weeks
Study NCT02839941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: All subjects will receive mycophenolate mofetil for consecutive 52 weeks
Study NCT03039179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: polyurethane foam dress
Description: Application of the polyurethane foam dress at the heel in the immediate postoperative period before applied the Walker
Study NCT00797329 — intervention group
Intervention type: OTHER
Intervention: chart review
Description: * cholesterol~* cognitive profiles~* violent behavior
Study NCT03949244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005%
Description: Latanoprost 0.005% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
Study NCT00643929 — intervention group
Intervention type: DRUG
Intervention: Eltrombopag
Description: Subjects participated in a prior eltrombopag study, having received either eltrombopag or placebo
Study NCT02839941 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Tacrolimus
Description: All subjects will receive tacrolimus for consecutive 52 weeks
Study NCT02839941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: All subjects will receive tacrolimus for consecutive 52 weeks
Study NCT02839941 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Glucocorticoids
Description: All subjects will receive glucocorticoids for consecutive 52 weeks
Study NCT03068078 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet high in monounsaturated fats
Description: Participants will have to change their diet during 6 months
Study NCT03202199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: 2 PET/MRI examinations
Study NCT03813498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HCV articles
Description: The intervention group receive a targeted short article on HCV from WeChat weekly.
Study NCT03813498 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: general health articles
Description: The control group receive a general health article with no mention of HCV from WeChat weekly.
Study NCT02944188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic right hemicolectomy plus ERAS
Description: patients treated with Laparoscopic right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
Study NCT02839941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: All subjects will receive glucocorticoids for consecutive 52 weeks
Study NCT03143556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic stent
Description: Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure will be assigned to magnetic stent or routine stent using computer generated randomization method in the operating room. Those who receive magnetic stent would get their stent removal by magnetic device retrieval and not by routine cystoscopy.
Study NCT02790554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moyo strap-on
Description: Continous monitoring
Study NCT02790554 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand-held Doppler
Description: Intermittent monitoring
Study NCT02236741 — intervention group
Intervention type: DRUG
Intervention: Mirapexin® (Sifrol®)
Study NCT02285712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular ultrasound system
Study NCT02576457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936559
Study NCT02576457 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Study NCT00855257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acid Nicotinique
Study NCT00855257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03114566 — intervention group
Intervention type: OTHER
Intervention: Leukapheresis
Description: Blood is removed together with an anticoagulant from a vein and separated into white cell rich and red cell rich fractions by centrifugation. The white cells are then saved to generate immune cells and the red cells are reinfused back through the donor's vein.
Study NCT00453843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rehabilitation robotics
Description: sequence of intervention
Study NCT00453843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Movement therapy
Description: sequence of intervention
Study NCT02608229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVD-523
Study NCT03949244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost bunod 0.024%
Description: Latanoprost bunod 0.024% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
Study NCT03949244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline 0.9%
Description: Normal saline 0.9% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
Study NCT03949244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Nailfold capillaroscopy
Description: An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.
Study NCT03949244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nailfold capillaroscopy
Description: An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.
Study NCT03949244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Nailfold capillaroscopy
Description: An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.
Study NCT01169532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: Given PO
Study NCT01169532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO
Study NCT01169532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies
Study NCT01169532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01169532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00782821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit Antithymocyte Globulin
Description: rATG will be given 1.5mg/kg intravenous (IV) per dose.
Study NCT00782821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit Antithymocyte Globulin
Description: rATG will be given 1.5mg/kg intravenous (IV) per dose.
Study NCT00782821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Velcade will be given 1.3mg/m2 via intravenous push (IVP) per dose.
Study NCT00782821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: Given via IV per group assignment.
Study NCT02666352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: A single dose of uprifosbuvir 450 mg (given as three 150-mg tablets) taken by mouth.
Study NCT02666352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: A single dose of ruzasvir 60 mg (given as six 10-mg capsules) taken by mouth.
Study NCT02884349 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RoM assessment
Description: This group will have a CT scan at three months post-operatively instead of the two radiographs, an anterior/posterior pelvis view and a lateral hip view, which are standard care. They will also have a RoM assessment session in the movement analysis laboratory in the hospital at the same time point lasting about one hour, which is additional to standard care.
Study NCT03633448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Children's Mucinex® Grape Flavor
Description: 1 x 200 mg (10 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
Study NCT03633448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Children's Mucinex® Grape Flavor
Description: 1 x 400 mg (20 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
Study NCT02608229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Study NCT02608229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02608229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Study NCT00673686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
Description: SH T 00186 D in a 24-day regimen, i.e., 24 verum tablets, 4 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
Study NCT00673686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yasminelle (SH T 00186 D)
Description: SH T 00186 D in a 21-day regimen, i.e., 21 verum tablets, 7 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
Study NCT03086681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar: 7.5mg/m2 d1-10, repeat every 15 days, for 4 cycles
Study NCT03086681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DDP
Description: DDP: 40mg /m2，per week, for 5 cycles
Study NCT03086681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDP
Description: DDP: 40mg /m2，per week, for 5 cycles
Study NCT04238676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP353
Description: active administered by intradiscal injection
Study NCT04238676 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham injection
Study NCT00078988 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV
Study NCT00078988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00078988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00078988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: Given IV
Study NCT00078988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Given IV
Study NCT00078988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Description: Peripheral blood stem cells or bone marrow will be reinfused about 72 hours following completion of the last dose of chemotherapy (Day 0)
Study NCT00078988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Filgrastim is to be given daily in the afternoon for 4 days prior to the first harvest and continued until the completion of the daily harvests. The daily PBSC harvesting should be started prior to the fifth dose of filgrastim.
Study NCT02913742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: monitoring by depth electrode
Description: During laser interstitial thermal ablation (LITT) for mesial temporal lobe epilepsy, the study patients will receive invasive neurophysiologic intraoperative monitoring. In addition to the typical placement of LITT stereotactic laser ablation probe via occipital burr hole, the study patients will receive an 8-contact depth recording electrode placed through an adjacent burr hole. The recording electrode will be placed into the parahippocampal gyrus in parallel to the LITT device. The patient will be monitored for epileptic discharges for 10 minutes before and 10 minutes after the ablation process to record the change in discharges during the surgery. The monitoring will not be used to guide surgery. The probe will be removed with the LITT device at the end of the procedure.
Study NCT03323996 — intervention group
Intervention type: OTHER
Intervention: Semi-Structured interviews
Description: individual semi-structured interviews
Study NCT00772694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: tablets 200mg, 400mg bid continuously in 4-week cycles
Study NCT02611700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 400mg,day1,weekly,until disease progression or toxicity
Study NCT02611700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175mg/m\^2,for 3 hour(Peripherally Inserted Central Catheter,PICC),day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.
Study NCT02611700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175mg/m\^2,for 3 hour(Peripherally Inserted Central Catheter,PICC),day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.
Study NCT02611700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 60mg/m\^2,day1，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.
Study NCT02611700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60mg/m\^2,day1，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.
Study NCT02611700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400mg,day1,weekly,until disease progression or toxicity